Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 19/20 | 0.69 |
| ▸ | SLC6A4 | P31645 | 19/20 | 0.69 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.69 |
| ▸ | HRH1 | P35367 | 5/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3328722 | 1.00 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| SCHEMBL3328727 | 1.00 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| Hydrochloric Acid SCHEMBL3324727 | 0.99 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| Hydrochloric Acid SCHEMBL3324722 | 0.99 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| SCHEMBL3176562 | 0.91 | SLC6A2 (0.73) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| SCHEMBL3175975 | 0.91 | SLC6A2 (0.73) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| Hydrochloric Acid SCHEMBL3333504 | 0.89 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3HRH1 | |
| Hydrochloric Acid SCHEMBL3333509 | 0.89 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3HRH1 | |
| SCHEMBL3333592 | 0.88 | SLC6A2 (0.86) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| SCHEMBL3333367 | 0.88 | SLC6A2 (0.86) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | FISH PAUL VINCENT | 2010-06-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | OPRL1, UGT1A1, HTR3B | SLC6A2 109/4885SLC6A4 113/4885SLC6A3 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.